---
schema_version: "secwatch.filing_event.v1"
accession: "0001232524-25-000009"
form_type: "8-K"
ticker: "JAZZ"
cik: "0001232524"
company_name: "Jazz Pharmaceuticals plc"
filed_at: "2025-02-25T23:59:59+00:00"
generated_at: "2026-05-26T04:26:25.187816+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Jazz Pharma reports record 2024 revenue $4.1B; guides 2025 rev $4.15-4.40B

## Summary
- Record total revenue $4.07B for FY2024, up 6% YoY; Q4 revenue $1.09B, up 8% YoY.
- GAAP diluted EPS $8.65 (FY2024) vs $6.10 (FY2023); Non-GAAP diluted EPS $20.90 vs $18.29.
- Xywav+Epidiolex grew 16% and 15% YoY; oncology revenue surpassed $1.1B (+9%).
- 2025 guidance: total revenue $4.15-4.40B; GAAP EPS $9.15-11.50; Non-GAAP EPS $22.50-24.00.
- Cash from ops $1.4B; voluntary $750M debt prepayment in Jan 2025; Ziihera launch initial sales $1.1M.

## SEC filing metadata
- accession: 0001232524-25-000009
- form_type: 8-K
- ticker: JAZZ
- cik: 0001232524
- company_name: Jazz Pharmaceuticals plc
- filed_at: 2025-02-25T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1232524/000123252425000009/0001232524-25-000009-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1232524/000123252425000009/jazz-20250225.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001232524-25-000009
- JSON: https://secwatch.observer/filing/0001232524-25-000009.json
- Plain text: https://secwatch.observer/filing/0001232524-25-000009.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.